Tinavi Medical TechnologiesLtd Gestione

Gestione criteri di controllo 2/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Jin Xu

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	no data
Proprietà del CEO	0.07%
Durata media del management	Nessun dato
Durata media del Consiglio di amministrazione	5.6yrs

Aggiornamenti recenti sulla gestione

Recent updates

What Tinavi Medical Technologies Co.,Ltd.'s (SHSE:688277) 60% Share Price Gain Is Not Telling You

Oct 09

Is Tinavi Medical TechnologiesLtd (SHSE:688277) A Risky Investment?

Jun 14

More Unpleasant Surprises Could Be In Store For Tinavi Medical Technologies Co.,Ltd.'s (SHSE:688277) Shares After Tumbling 26%

Apr 21

There's Reason For Concern Over Tinavi Medical Technologies Co.,Ltd.'s (SHSE:688277) Massive 25% Price Jump

Mar 06

Health Check: How Prudently Does Tinavi Medical TechnologiesLtd (SHSE:688277) Use Debt?

Feb 27

AMMINISTRATORE DELEGATO

Jin Xu (50 yo)

no data

Mandato

CN¥1,171,000

Compensazione

Mr. Jin Xu serves as the General Manager and Director of TINAVI Medical Technologies Co., Ltd.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Jin Xu	GM & Director	no data	CN¥1.17m	0.071% CN¥ 3.3m
Min Ma	President & Director	no data	Nessun dato	Nessun dato
Yang Xu	Independent Director	1.2yrs	Nessun dato	Nessun dato
Ruijun Zhang	Independent Director	1.2yrs	Nessun dato	Nessun dato
Changjiu Dai	Independent Director	5.6yrs	CN¥100.00k	Nessun dato
Dequan Zhu	Director	14.1yrs	Nessun dato	Nessun dato
Zhi Xiao	Director	6yrs	Nessun dato	Nessun dato
Songgen Zhang	Chairman	14.1yrs	CN¥1.22m	16.84% CN¥ 771.0m
Binbin Wang	Director	8.8yrs	CN¥976.00k	0.024% CN¥ 1.1m
Guangzhi Wang	Independent Director	5.6yrs	CN¥100.00k	Nessun dato
Zhaoqi Zhu	Supervisor	4.2yrs	Nessun dato	Nessun dato
Chi Yung Lee	Independent Director	1.2yrs	Nessun dato	Nessun dato

5.6yrs

Durata media

57yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 688277 sono considerati esperti (durata media dell'incarico 5.6 anni).

Tinavi Medical TechnologiesLtd Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Tinavi Medical Technologies Co.,Ltd., Annual General Meeting, Jun 27, 2024

Less than half of directors are independent

Recent updates

Third quarter 2024 earnings released: CN¥0.072 loss per share (vs CN¥0.082 loss in 3Q 2023)

What Tinavi Medical Technologies Co.,Ltd.'s (SHSE:688277) 60% Share Price Gain Is Not Telling You

New minor risk - Share price stability

Tinavi Medical Technologies Co.,Ltd. to Report Q3, 2024 Results on Oct 30, 2024

Second quarter 2024 earnings released: CN¥0.085 loss per share (vs CN¥0.093 loss in 2Q 2023)

Tinavi Medical Technologies Co.,Ltd. to Report First Half, 2024 Results on Aug 28, 2024

Is Tinavi Medical TechnologiesLtd (SHSE:688277) A Risky Investment?

Tinavi Medical Technologies Co.,Ltd., Annual General Meeting, Jun 27, 2024

Full year 2023 earnings released: CN¥0.35 loss per share (vs CN¥0.26 loss in FY 2022)

More Unpleasant Surprises Could Be In Store For Tinavi Medical Technologies Co.,Ltd.'s (SHSE:688277) Shares After Tumbling 26%

Tinavi Medical Technologies Co.,Ltd. to Report Q1, 2024 Results on Apr 27, 2024

There's Reason For Concern Over Tinavi Medical Technologies Co.,Ltd.'s (SHSE:688277) Massive 25% Price Jump

Full year 2023 earnings released: CN¥0.36 loss per share (vs CN¥0.26 loss in FY 2022)

Health Check: How Prudently Does Tinavi Medical TechnologiesLtd (SHSE:688277) Use Debt?

Third quarter 2023 earnings released: CN¥0.082 loss per share (vs CN¥0.088 loss in 3Q 2022)

Second quarter 2023 earnings released: CN¥0.093 loss per share (vs CN¥0.039 loss in 2Q 2022)

TINAVI Medical Technologies Co., Ltd. to Report Q2, 2023 Results on Aug 23, 2023

Full year 2022 earnings released: CN¥0.26 loss per share (vs CN¥0.19 loss in FY 2021)

Full year 2022 earnings released: CN¥0.27 loss per share (vs CN¥0.19 loss in FY 2021)

Beijing Huilin Oriental Technology Partnership Enterprise (Limited Partnership) and Wang Binbin entered into an agreement to acquire 12% stake in Beijing Shuimu Dongfang Medical Robotics Technology Innovation Center Co., Ltd. from TINAVI Medical Technologies Co., Ltd. (SHSE:688277).

Less than half of directors are independent

Third quarter 2022 earnings released: CN¥0.088 loss per share (vs CN¥0.06 loss in 3Q 2021)

Second quarter 2022 earnings released: CN¥0.039 loss per share (vs CN¥0.031 loss in 2Q 2021)

First quarter 2022 earnings released: CN¥0.07 loss per share (vs CN¥0.06 loss in 1Q 2021)

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Third quarter 2021 earnings released: CN¥0.06 loss per share (vs CN¥0.04 loss in 3Q 2020)

Second quarter 2021 earnings released: CN¥0.031 loss per share (vs CN¥0.049 loss in 2Q 2020)

TINAVI Medical Technologies Co., Ltd. announced that it expects to receive CNY 1.34 billion in funding

First quarter 2021 earnings released: CN¥0.06 loss per share (vs CN¥0.04 loss in 1Q 2020)

Full year 2020 earnings released: CN¥0.14 loss per share (vs CN¥0.08 loss in FY 2019)

New 90-day low: CN¥34.82

New 90-day low: CN¥45.92

New 90-day low: CN¥55.62

TINAVI Medical Technologies Co., Ltd. to Report First Half, 2020 Results on Aug 25, 2020